NL-OMON32554尚未招募不适用
Dendritic cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesothelioma - DC-immunotherapy and cyclophosphamide in treating mesothelioma
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •As for our earlier study (MEC-2005-269):;Patients with clinically and histological or cytological confirmed newly diagnosed mesothelioma, that can be measured in two dimensions by a radiologic imaging study.
- •Patients must be at least 18 years old and must be able to give written informed consent.
- •Patients must be ambulatory (Karnofsky scale > 70, or WHO-ECOG performance status 0,1, or 2) and in stable medical condition. The expected survival must be at least 4 months.
- •Patients must have normal organ function and adequate bone marrow reserve: absolute neutrophil count > 1.5*109/l, platelet count > 100*109/l, and Hb > 6.0 mmol/l.
- •Positive delayed type hypersensitivity skin test (induration > 2mm after 48hrs) against at least one positive control antigen of MULTITEST CMI (Pasteur merieux).
- •Stable disease or response after chemotherapy.
- •Availability of sufficient tumor material of the patient.
- •Ability to return to the Erasmus MC for adequate follow-up as required by this protocol. ;New for this study (in comparison to MEC-2005-269) are:
- •Able to tolerate oral therapy
- •No impairment of gastrointestinal (GI) function or GI disease that may affect or alter absorption of cyclophosphamide (e.g., mal-absorption syndrome, history of total gastrectomy/significant small bowel resection)
- •No history of allergic reactions (>= grade 3 or 4) to compounds of similar chemical or biologic composition to cyclophosphamide (i.e., alkylating agents)
- •No known intolerance or hypersensitivity reaction to cyclophosphamide
排除标准
- •As for our earlier study (MEC-2005-269):;Conditions that make the patient unfit for chemotherapy or progressive disease after 4 cycles of chemotherapy.
- •Pleurodesis at the affected side before the pleural fluid is obtained.
- •Medical or psychological impediment to probable compliance with the protocol.
- •Patients on steroid (or other immunosuppressive agents) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation and must stop of any such treatment during the time of the study.
- •No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, superficial or in-situ cancer of the bladder or other cancer for which the patient has been disease-free for five years.
- •Serious concomitant disease, no active infections. Patients with a history of autoimmune disease or organ allografts, or with active acute or chronic infection, including HIV and viral hepatitis.
- •Patients with serious intercurrent chronic or acute illness such as pulmonary (asthma or COPD) or cardiac (NYHA class III or IV) or hepatic disease or other illness considered by the study coordinators to constitute an unwarranted high risk for investigational DC treatment.
- •Patients with a known allergy to shell fish (contains KLH).
- •Pregnant or lactating women.
- •Patients with inadequate peripheral vein access to perform leukapheresis
- •Concomitant participation in another clinical trial
- •An organic brain syndrome or other significant psychiatric abnormality which would comprise the ability to give informed consent, and preclude participation in the full protocol and follow-up.
- •Absence of assurance of compliance with the protocol. Lack of availability for follow-up assessment. ;No additiona exclusion criteria in comparison to MEC-2005-269
研究者
相似试验
已完成
不适用
Dendritic cell-based immunotherapy for ovrian cancer patients.NeoplasmsKCT0000831Asan Medical Center10
进行中（未招募）
1 期
Dendritic cell-based immunotherapy for advanced solid tumours of children and young adultsChildren and young adults with advanced solid tumours: relapsed or metastatic sarcomas or central nervous system tumours.EUCTR2013-003632-71-ESClínica Universidad de Navarra/Universidad de Navarra10
进行中（未招募）
不适用
Dendritic cell-based Immunotherapy in patients with primary glioblastoma multiformeNeoplasmsKCT0000280Bundang CHA General Hospital13
招募中
不适用
Immuun interventie met tolerogene dendritische cellen (DC) in type 1 diabetes. Eerste klinische veiligheidsstudie genaamd D-senseDiabetes Mellitus, Type 1ImmunotherapyDendritic cellsSafetyType 1 diabetesImmunotherapieDendritische cellenVeiligheidNL-OMON21892eiden Universitu Medical Center9
招募中
不适用
Immune intervention with tolerogenic dendritic cells in type 1 diabetes. A phase 1 safety study called D-sensediabetestype 1 diabetes10018424NL-OMON50354eids Universitair Medisch Centrum9